Generic · Injection
Gentamicin 10 mg/mL, 2 mL injection price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for gentamicin 10 mg/ml, 2 ml injection this week. The makers, package codes, recalls and label are below.
What people paid for gentamicin 10 mg/ml, 2 ml injection
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 40 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
2 companies sell gentamicin 10 mg/ml, 2 ml injection under 4 package codes (NDCs).
| Maker | Package codes | Per unit |
|---|---|---|
| Eugia US LLC | 55150-401-25 | - |
| Fresenius Kabi USA, LLC | 63323-173-02 63323-173-94 63323-173-95 | - |
All 4 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Other gentamicin strengths and forms
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 1 mg/mL cream | $0.8943 | $13.41 / 15 g |
| 3 mg/mL eye drops | $0.9073 | $4.54 / 5 mL |
| 40 mg/mL injection | $1.26 | $62.88 / 50 mL |
| 40 mg/mL, 2 mL injection | $1.26 | $2.52 / 2 mL |
| 0.001 mg/mg ointment | $0.7378 | $11.07 / 15 g |
Official label & what changed
Gentamicin Injection, USP
BOXED WARNINGS
Patients treated with aminoglycosides should be under close clinical observation because of the potential toxicity associated with their use.
As with other aminoglycosides, gentamicin injection is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosage of prolonged therapy.
Neurotoxicity manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in those with pre- existing renal damage and in patients with normal renal function treated with higher doses and/or for longer periods than recommended.
Aminoglycoside-induced ototoxicity is usually irreversible. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions.
Renal and eighth cranial nerve function should be closely monitored, especially in patients with known or suspected reduced renal function at onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Urine should be examined for decreased specific gravity, increased excretion of protein and the presence of cells or casts. Blood urea nitrogen (BUN), serum creatinine or creatinine clearance should be determined periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears or hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug. As with the other aminoglycosides, on rare occasions changes in renal and eighth cranial nerve function may not become manifest until soon after completion of therapy.
Serum concentrations of aminoglycosides should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. When monitoring gentamicin peak concentrations, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided. When monitoring gentamicin trough concentrations, dosage should be adjusted so that levels above 2 mcg/mL are avoided. Excessive peak and/or trough serum concentrations of aminoglycosides may increase the risk of renal and eighth cranial nerve toxicity.
In the event of overdosage or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably lower by peritoneal dialysis than it is by hemodialysis.
In the newborn infant, exchange transfusions may also be considered.
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin and viomycin, should be avoided. Other factors which may increase patient risk of toxicity are advanced age and dehydration.
The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue.
Aminoglycosides can cause fetal harm when administered to a pregnant woman (see WARNINGS section).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about gentamicin 10 mg/ml, 2 ml injection
Who makes gentamicin 10 mg/ml, 2 ml injection?
2 companies: Eugia US LLC, Fresenius Kabi USA, LLC. See every package code.
Is gentamicin in shortage?
No shortage is reported right now. We check every day.
Has gentamicin been recalled?
40 recalls on record, 5 ongoing. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about gentamicin 10 mg/ml, 2 ml injection
No comments yet. Questions, tips, what worked for you - start the conversation.